systems and packaging solutions, as well as East Pack which offers the premier industry resource for East Coast packaging and manufacturing sectors. The events will also be collocated with Medical Design & Manufacturing (MD&M) East which is the longest running medical design and manufacturing event in the world. The combined events will capitalise on cross over traffic and the synergies between the shows with the aim of strengthening existing relationships while creating additional business opportunities for attendees and exhibitors alike.
"As US companies' race against the expiration of blockbuster drugs, there has been a huge push towards the development of biosimilars and biologics to fill the needs of the market. Coupled with the introduction of the Patient Protection and Affordable Care Acts, which highlight the need to make quality pharmaceuticals more accessible to all citizens, all of these factors have created a massive drive for R&D in the US market. Running R&D and clinical trials in the US is expensive and directly increases the demand for comprehensive contract and outsourcing resources in this market," said Haf Cennydd, Global Brand Director of ICSE. She went on to note, "Despite tough market conditions, the US remains the largest pharmaceutical market in the world, accounting for 39% of the total $795bn generated by Pharma annually. It is expected to continue to grow at an average rate of 5% per year, leading to a market value of $399bn in 2015(1)."
The UBM Live annual schedule of ICSE events also includes India (30 November – 2 December, Bombay Exhibition Centre, Mumbai, India, 2011), Japan (21-23, March, Big Sight Tokyo Exhibition Center, Japan, 2012), China (26-28, June, SNIEC, Shanghai, China, 2012), South America (21-23, August, Transamerica Expo Centre, Sao Paulo, Brazil 2012) and Worldwide (9-11 October, 2012 at the Feria de Madrid, Spain).
(1)Pharma Outsourcing in the USA, UBM commissioned rePage: 1 2 3 Related medicine technology :1
. FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers Access to Lower-Cost Generic Drugs2
. INNOPHARMA Receives FDA Approval of Generic Olanzapine Injection3
. WuXi PharmaTech Schedules Third-Quarter 2011 Earnings Release4
. Latest Pharmaceutical Launch Strategies Demonstrate Growing Importance of Thought Leader Engagement at Market Entry5
. Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality6
. Webcast Alert: Isis Pharmaceuticals Third Quarter 2011 Financial Results Conference Call7
. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value8
. Gamma Pharmaceuticals, Inc., Launches Retail Promotions for Gamma Energy Gel™ in New York City and Houston9
. Vanda Pharmaceuticals Appoints Chief Commercial Officer10
. Par Pharmaceutical Begins Shipment of Generic Zyprexa® Zydis®11
. Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape